Q-omics provides the consensus-scored DPYSL3 profile across patient tissues and cancer cell-line models. DPYSL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DPYSL3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DPYSL3 protein abundance shows 26,977 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where DPYSL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPYSL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPYSL3 survival associations across molecular data types. DPYSL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPYSL3 RNA expression–survival associations across cancer types. High DPYSL3 expression shows unfavorable associations in KIRP, MESO, BLCA and UVM, but favorable associations in LGG and DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DPYSL3 RNA expression.
This table summarizes DPYSL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DPYSL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPYSL3 shows lower tumor expression in UCEC, BLCA and BRCA and higher tumor expression in KIRC, THCA and LIHC. The KIRC box plot shows higher DPYSL3 RNA expression in tumor versus normal tissue (log2 FC = +1.339, t-test p < 0.001).
This table shows molecular features associated with DPYSL3 in patient tissues and cancer cell lines. In patient samples, DPYSL3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DPYSL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
